ArticleJournal of medicinal chemistry2019
The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- The structure of the dopamine DScience advances · 2026Article
- A Ligand-Triggered Receptor Conformation Enables the Design of Selective Agonists for the Dopamine 3 Receptor (DJACS Au · 2026Article
- Bioisosteric Replacement of Amides with 1,2,3-Triazoles Improves Dopamine D4 Receptor Ligand Pharmacokinetics.ACS pharmacology & translational science · 2026Article
- Review
- Locomotor activity depends on β-arrestin recruitment by the dopamine DPharmacological research · 2025Article
- The Importance of Stereochemistry in 5-HTACS chemical neuroscience · 2024Article
- Involvement of dopamine D3 receptor in impulsive choice decision-making in male rats.Neuropharmacology · 2024Article
- A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site.Nature communications · 2024Article
- Linkers in Bitopic Agonists Shape Bias Profile among Transducers for the Dopamine D2 and D3 Receptors.ACS pharmacology & translational science · 2024Article
- Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing.Acta pharmaceutica Sinica. B · 2024Review
- Structure of the dopamine D3 receptor bound to a bitopic agonist reveals a new specificity site in an expanded allosteric pocket.Research square · 2023Article
- Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder.Journal of medicinal chemistry · 2023Article
- Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent DInternational journal of molecular sciences · 2022Article
- Pharmacological targeting of G protein-coupled receptor heteromers.Pharmacological research · 2022Article
- Identification of Novel Dopamine DMolecules (Basel, Switzerland) · 2022Article
- The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.Frontiers in pharmacology · 2022Review
- Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine DJournal of medicinal chemistry · 2021Article
- Structure Activity Relationships for a Series of Eticlopride-Based Dopamine DJournal of medicinal chemistry · 2021Article
- Novel Dual-Target μ-Opioid Receptor and Dopamine DJournal of medicinal chemistry · 2021Article
- Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.Biomolecules · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Francisco O BattitiMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Sophie L CemajMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Adrian M GuerreroMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Anver Basha ShaikMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Jenny LamMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.
Rana RaisJohns Hopkins Drug Discovery Program , Johns Hopkins School of Medicine , 855 N. Wolfe Street , Baltimore , Maryland 21205 , United States.ORCID 0000-0003-4059-2453
Barbara S SlusherJohns Hopkins Drug Discovery Program , Johns Hopkins School of Medicine , 855 N. Wolfe Street , Baltimore , Maryland 21205 , United States.ORCID 0000-0001-9814-4157
Jeffery R DeschampsNaval Research Laboratory , Code 6910, 4555 Overlook Avenue , Washington, DC 20375 , United States.
Greg H ImlerNaval Research Laboratory , Code 6910, 4555 Overlook Avenue , Washington, DC 20375 , United States.
Amy Hauck NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.ORCID 0000-0001-9065-4072
Alessandro BonifaziMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program , National Institutes of Health , 333 Cassell Drive , Baltimore , Maryland 21224 , United States.ORCID 0000-0002-7306-0114
National Institutes of Health · USJohns Hopkins University · USUnited States Naval Research Laboratory · US
Funding
Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9MDopamine D2-like Functionally Selective AgonistsZIADA000609 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2016 to 2020
$2.8MNOVEL DOPAMINE D3 RECEPTOR LIGANDSZ01DA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 1999 to 2008
$1.8MIntramural NIH HHS Z01 DA000424Intramural NIH HHS ZIA DA000424Intramural NIH HHS ZIA DA000609
Abstract
Because of the large degree of homology among dopamine D
Indexed as
AnimalsDopamine AgonistsDrug DesignHEK293 CellsHumansIndolesLigandsMicrosomes, LiverRatsReceptors, Dopamine D3StereoisomerismStructure-Activity RelationshipDopamine AgonistsIndolesLigandsReceptors, Dopamine D3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.